latest news releases from the newsroom
Chelsea Therapeutics Completes Phase Ia Trial of CH-1504
CHARLOTTE, N.C., Oct. 20, 2005 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:CHTP), has successfully completed the Phase Ia trial of its leading drug candidate, CH-1504, an orally available, metabolically inert, anti-inflammatory and anti-tumor agent for the treatment of rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease and certain cancers. In this single ascending dose study, the compound was safe and well tolerated across a broad dose range with no clinically significant observations noted.
Bayfield Ventures Corp.
Bayfield Ventures Provides Corporate Update
VANCOUVER, British Columbia, Oct. 20, 2005 (PRIMEZONE) -- Bayfield Ventures Corp. (Bayfield) (TSX-V:BYV) is pleased to provide this update to its shareholders. The Company has 100% of approximately 300,000 hectares (760,000 acres) contained in 3 mineral licenses in the South Gobi Region of Mongolia. A significant achievement in 2005 was the optioning of all three of Bayfield's Mongolian properties to BHP Billiton World Exploration Inc., the world's largest diversified resources company. Bayfield Ventures has been exploring for mineral deposits in Mongolia since 2001. The Company's land packages are ideally located to the immediate west and east of the world-class copper-gold deposit (Oyu Tolgoi) that is now being defined for production by Ivanhoe Mines Ltd. With the addition of the skilled and experienced people of BHP Billiton being responsible for the new work programs on Bayfield's acreage in Mongolia, the Company believes this could be its ultimate key to success in the lower Gobi Region of Mongolia.
Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals to Present at C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
NEW YORK, Oct. 20, 2005 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) will be presenting at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference on Tuesday, October 25th at 3:20 p.m. EDT at The Palace Hotel in New York City. Douglas Abel, President and CEO, will provide a corporate overview, including a review of the Company's lead product candidate Oleoyl-estrone (OE), an experimental, orally administered small molecule in development for the treatment of obesity.
Ringo Introduces 'Cost by Radius' Advertising Model
BOCA RATON, Fla., Oct. 20, 2005 (PRIMEZONE) -- Ringo, Inc. (Pink Sheets:RGOI) is pleased to introduce a patent pending proximity based advertising model to its location based service offerings. Ringo's new advertising model, a form of Location Based Advertising, is designed to maximize the effectiveness of advertising budgets by marketing directly to individual consumers located within a specific proximity of a business.
UCB Confirms Good Performance of Zyrtec in U.S. and Xyzal
BRUSSELS, Belgium, Oct. 20, 2005 (PRIMEZONE) -- Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec continues to strengthen its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The U.S. in-market sales of Zyrtec have reached $1,035 million during the past 9 months ending September 30th, 2005 showing a 10% increase against the same period in 2004, while the antihistamine market decreased by 5%(1).